Le Lézard
Classified in: Business
Subject: ATY

Zantac Lawsuit


NEW YORK, July 6, 2020 /PRNewswire/ -- Attorney Advertising -- Have you taken Zantac and been diagnosed with Cancer? The Zantac lawsuit claims that Zantac can be contaminated with the cancer-causing substance N-nitrosodimethylamine (NDMA).

If you or a loved one took Zantac and have been diagnosed with any of these cancers, contact us now!

For more information, visit: www.bgandg.com/zantac.  

On September 13, 2019, the U.S. Food and Drug Administration ("the FDA") announced the risk of cancer from Zantac from a chemical contamination. The FDA described how the medications containing ranitidine, including Zantac (ranitidine), contains trace amounts of N-nitrosodimethylamine (NDMA) and that testing has confirmed NDMA to be a potent carcinogen. The FDA continued to state that Zantac has been found to contain these carcinogenic chemicals at 26,000 times the FDA approved.

Since this contamination was first discovered, there have been several Zantac recalls. On September 23, 2019, Sandoz issued the first recall, followed by several generic Zantac makers that supply for Walgreens, Walmart, Rite Aid and CVS. Sanofi, makers of the brand name Zantac issued a recall on October 18, 2019.

The FDA advised the public that it is okay to continue to take over the counter Zantac and other ranitidine medications, and anyone taking prescription Zantac should consult with their physicians if an alternative treatment is available.

Bronstein Gewirtz And Grossman is working tirelessly to alert consumers and to help consumers find out their rights. If you or a loved one have taken Zantac at any time between January 1, 2010 to present and have been diagnosed with Cancer, then you may be eligible for compensation. Know your rights! Reach out to Bronstein Gewirtz and Grossman LLC today. For more information, visit: www.bgandg.com/zantac.  

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein
212-697-6484 | [email protected]

SOURCE Bronstein, Gewirtz & Grossman, LLC


These press releases may also interest you

at 11:55
The following amendment has been made to the "Dividend Declaration" announcement released on April 23, 2024. The Record date has been corrected from September 2, 2024 to September 3, 2024. All other details remain unchanged. Neither the TSX...

at 11:55
Ninepoint Partners LP ("Ninepoint") is pleased to announce that the Ninepoint 2024 Short Duration Flow-Through Limited Partnership (the "Partnership") has completed the third and final closing in connection with its offering of limited partnership...

at 11:52
The Secure Cash & Transport Association (SCTA) announces sponsorship opportunities for its 2024 conference taking place October 9-11...

at 11:50
Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, "Median" or the "Company") today reported its 2023 consolidated annual financial results, as of December 31, 2023, and provided financial information (unaudited)...

at 11:45
OneShield, a leader in insurance technology solutions, is pleased to announce its partnership with One Inc, a leading provider of digital payment solutions for the insurance industry. One Inc's payment products integrations will now be accessible...

at 11:43
Join early childhood leaders, practitioners, researchers, and government representatives for "The Summer Institute on Early Childhood Development" where an urgently needed workforce standards action plan for the sector will be developed. Hosted by...



News published on and distributed by: